Nathan K. LeBrasseur, Ph.D., M.S.

Closed for Enrollment

• A 28 Week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia Rochester, Minn.

  The purpose of this study is to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study will generate data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.

• A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility Rochester, Minn.

  The purpose of this study is to investigate the effect of CK-2127107 versus placebo on skeletal muscle fatigue assessed as change from baseline versus 14 days of treatment in sum of peak torque during isokinetic knee extensions. This study will also assess the effects of CK-2127107 on physical performance via a short physical performance battery (SPPB), stair-climb test and 6 minute walk test.

• The Effects of an Active Older Adult Program at the Dan Abraham Healthy Living Center on Health and Well-being Rochester, Minn.

  The purpose of this study is to determine whether a structured 12-week program designed for older adults will improve physical function and well-being.
   

• The Impact of Frailty on Health Outcomes following Aortic Valve Replacement Rochester, Minn.

  The purpose of this study is to determine what factors predict poor surgical outcomes, and the extent to which patient-centered outcomes differ between participants deemed frail and non-frail.